Equillium Stock Today

EQ -  USA Stock  

USD 5.42  0.13  2.34%

Equillium is selling at 5.42 as of the 1st of August 2021; that is -2.34 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 5.39. Equillium has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Equillium are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of July 2021 and ending today, the 1st of August 2021. Click here to learn more.
 Market Performance
0 of 100
  Odds Of Distress
Less than 3

Equillium Stock Profile

The upcoming quarterly report is expected on the 11th of August 2021. Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. Equillium operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people. more on Equillium
Equillium generates negative expected return over the last 90 days
Equillium has high historical volatility and very poor performance
Annual Net Loss to common stockholders was (30.97 M).
Equillium reports about 104.08 M in cash with (26.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.58.
Equillium has a frail financial position based on the latest SEC disclosures
Roughly 53.0% of the company shares are held by company insiders
Latest headline from www.equities.com: Equillium falls 2.34 percent to Close at 5.42 on July 30 - Equities.com
Equillium Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Equillium SEC Filings
Equillium SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameEquillium
President CEO, DirectorGeoffrey Rotstein  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
  Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Equillium report their recommendations after researching Equillium's financial statements, talking to executives and customers, or listening in on Equillium's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Equillium. The Equillium consensus assessment is calculated by taking the average forecast from all of the analysts covering Equillium.
Strong Buy4 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Equillium based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Equillium financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares20.3 M20.4 M
Slightly Down
Slightly volatile
Weighted Average Shares Diluted20.3 M20.4 M
Slightly Down
Slightly volatile
Total Assets85.1 M85.4 M
Slightly Down
Slightly volatile
Total Liabilities14.3 M15.6 M
Significantly Down
Slightly volatile
Current Assets84.9 M85.2 M
Slightly Down
Slightly volatile
Current Liabilities6.4 M7.2 M
Fairly Down
Slightly volatile
Total Debt10.9 M9.9 M
Significantly Up
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Equillium's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Equillium's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Equillium's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Equillium's financial leverage. It provides some insight into what part of Equillium's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Equillium's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Equillium deploys its capital and how much of that capital is borrowed.
Equillium cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company reports 10.01 M of total liabilities with total debt to equity ratio (D/E) of 0.11, which may suggest the company is not taking enough advantage from financial leverage. Equillium has a current ratio of 14.08, indicating that it is in good position to pay out its debt commitments in time.

Operating Cash Flow

(26.57 Million)Share
Equillium (EQ) is traded on NASDAQ Exchange in USA. It is located in 2223 Avenida De La Playa and employs 31 people. Equillium is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with market capitalization of 169.6 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Equillium's market, we take the total number of its shares issued and multiply it by Equillium's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Equillium is active under Healthcare sector as part of Biotechnology industry. The entity has 29.04 M outstanding shares of which 1.14 M shares are currently sold short in the market by investors with about 9.13 days to cover all shorted shares. Equillium reports about 104.08 M in cash with (26.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.58.
Check Equillium Probability Of Bankruptcy
Equillium holds a total of twenty-nine million fourty thousand outstanding shares. Equillium retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Equillium Ownership Details

Equillium Stock Price Odds Analysis

What are Equillium's target price odds to finish over the current price? Contingent on a normal probability distribution, the odds of Equillium jumping above the current price in 90 days from now is about 87.12%. The Equillium probability density function shows the probability of Equillium stock to fall within a particular range of prices over 90 days. Allowing for the 90-day total investment horizon Equillium has a beta of 0.2674 suggesting as returns on the market go up, Equillium average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Equillium will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Equillium is significantly underperforming DOW.
 Odds Down 5.42HorizonTargetOdds Up 5.42 
12.80%90 days
Based on a normal probability distribution, the odds of Equillium to move above the current price in 90 days from now is about 87.12 (This Equillium probability density function shows the probability of Equillium Stock to fall within a particular range of prices over 90 days) .

Equillium Historical Income Statement

Equillium Income Statement is one of the three primary financial statements used for reporting Equillium's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Equillium revenue and expense. Equillium Income Statement primarily focuses on the company's revenues and expenses during a particular period.
View More Fundamentals

Equillium Stock Against Markets

Picking the right benchmark for Equillium stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Equillium stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Equillium is critical whether you are bullish or bearish towards Equillium at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Equillium without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Instant Ratings Now


Instant Ratings

Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Equillium Corporate Directors

Equillium corporate directors refer to members of an Equillium board of directors. The board of directors generally takes responsibility for the Equillium's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Equillium's board members must vote for the resolution. The Equillium board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
John Fisher - Independent DirectorProfile
Anthony Tjan - Independent DirectorProfile
Marc Lavine - Independent DirectorProfile
Charles McDermott - Independent DirectorProfile
Continue to Investing Opportunities. Note that the Equillium information on this page should be used as a complementary analysis to other Equillium's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Equillium Stock analysis

When running Equillium price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
The market value of Equillium is measured differently than its book value, which is the value of Equillium that is recorded on the company's balance sheet. Investors also form their own opinion of Equillium's value that differs from its market value or its book value, called intrinsic value, which is Equillium's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Equillium's market value can be influenced by many factors that don't directly affect Equillium underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Equillium's value and its price as these two are different measures arrived at by different means. Investors typically determine Equillium value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Equillium's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.